• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Novonesis

424.00 DKK-1.05 %8.7. klo 16.05
Less than 1K followers

NSIS B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-1.05 %
+15.50 %
+7.34 %
+4.05 %
+3.97 %
-7.61 %
+32.13 %
-11.50 %
+1,045.95 %

Novonesis is a biochemistry company. The company develops enzymes and various microorganisms for industrial use. The enzymes are a protein used in a number of different industries, mainly in the agricultural and food industries. Novonesis products are used in various foods and clothing and the company holds sales on a global level. Novonesis was founded in 1921 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
198.56B DKK
Turnover
101.17M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release06.05.2026 klo 15.44

Trading by management and close relations of management

Novonesis
Regulatory press release05.05.2026 klo 08.58

Interim report Q1 2026

Novonesis
Regulatory press release26.03.2026 klo 15.44

Trading by management and close relations of management

Novonesis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release23.03.2026 klo 18.54

Resolutions from the Annual General Meeting 2026

Novonesis
Regulatory press release23.03.2026 klo 14.52

Trading by management and close relations of management

Novonesis
Press release16.03.2026 klo 14.14

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis
Press release13.03.2026 klo 10.56

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis
Regulatory press release11.03.2026 klo 14.38

Trading by management and close relations of management

Novonesis
Regulatory press release27.02.2026 klo 11.22

Trading by management and close relations of management

Novonesis
Regulatory press release26.02.2026 klo 18.04

Trading by management and close relations of management

Novonesis
Regulatory press release26.02.2026 klo 13.00

Invitation to the 2026 Annual General Meeting

Novonesis
Regulatory press release26.02.2026 klo 12.23

Trading by management and close relations of management

Novonesis
Regulatory press release25.02.2026 klo 09.09

Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees

Novonesis
Regulatory press release25.02.2026 klo 08.57

Novonesis' Annual Report 2025

Novonesis
Regulatory press release21.11.2025 klo 11.47

Trading by management and close relations of management

Novonesis
Regulatory press release07.11.2025 klo 17.39

Trading by management and close relations of management

Novonesis
Regulatory press release07.11.2025 klo 11.34

Major shareholder announcement

Novonesis
Press release06.11.2025 klo 12.12

Novonesis delivered 8% organic sales growth in the first nine months of 2025

Novonesis
Regulatory press release06.11.2025 klo 08.57

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.

Novonesis
Regulatory press release04.11.2025 klo 16.11

Trading by management and close relations of management

Novonesis